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socio-economic circumstances & eating habits.
Step 2. How kidneys work. The damaged kidney is portrayed as a sieve with
very ﬁne mesh that does not allow normal kidney functions. Once the patient
understands that his uremic symptoms are related to diet & damaged kidneys,
he is willing to change his old eating habits. RRT is explained visually.
Step 3. What to eat. The calculated, technical diet prescription is explained
in an understandable way by a visual tool called ‘‘The renal plate’’ that was
speciﬁcally developed. The Renal plate is based on adjusting the Basic 3 Food
Groups by making use of the South African Renal exchange lists.
Step 4. What not to eat. Foods to avoid due to high sodium, phosphate &
potassium are presented by illustrations.
Step 5. How much to eat. Portion sizes are addressed through visuals since
‘‘The renal plate’’ only focuses on types of foods in a speciﬁc food group, not on
quantity of each food group to be eaten.
Compliance to a renal diet is an integral part of patient care. If
understandable renal diet education is linked to uremic symptoms & starts as
soon as the patient is diagnosed, there is far better future diet compliance &
disease outcome.
http://dx.doi.org/10.1016/j.krcp.2012.04.584261
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Fibroblast growth factor-23 (FGF-23) regulates phosphate metabolism and
elevated levels occur in patients with kidney disease and are associated with
smortality in maintenance hemodialysis (MHD) patients. Residual renal
function (RRF) presumably improves phosphate metabolism in MHD patients.
We investigated the role of circulating FGF-23 on urinary phosphate excretion
and phosphate balance in 134 MHD patients. Demographics, laboratory data,
and excretion capacity of phosphate were recorded. We used multivariable
regression to analyze the relationship of serum phosphate with other factors
and of the tubular reabsorption rate of phosphate with other factors. Patients
with high urinary output (4200 mL/day) had lower serum phosphate, calcium,
iPTH, and FGF-23 than patients with low urinary output (o 200 mL/day). The
independent risk factors for elevated serum phosphate were nPNA, iPTH, and
FGF-23 in patients with low urinary output, and female gender and GFR in
patients with high urinary output. In high urinary output patients, the weekly
phosphate excretion was 300 to 1500 mg, the renal contribution to weekly
phosphate elimination was about 15% when GFR o 2 mL/min, 25% when 2r
GFR o 5mL/min, and 40% when GFR Z 5mL/min. The tubular reabsorption of
phosphate (44% 7 19%) was nearly 50% of the normal level, much lower than
that of sodium, chlorine, and calcium which ranged from 85% to 99%. Elevated
circulating FGF-23 was signiﬁcantly associated with decreased tubular
phosphate reabsorption after adjusting for GFR and serum phosphate (b¼-
0.147, p¼0.003). In conclusion, RRF is associated with signiﬁcant capacity to
excrete phosphate and high levels of FGF-23 promote phosphate excretion in
remnant nephrons.
http://dx.doi.org/10.1016/j.krcp.2012.04.585262
IMPACT OF NLRP3 INFLAMMASOME ON THE DEVELOPMENT OF
HYPERTENSION AND RENAL AND CARDIAC HYPERTROPHY IN 2K1C AND
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Biochemistry, Lausanne University, Switzerland
NLRP3 inﬂammasome is formed by NLRP3, the adaptor ASC, and caspase-1,
functions as a sensor of danger signals and triggers processing and release of
interleukin-1beta (IL-1b). Recent animal studies demonstrate that NLRP3
inﬂammasome promotes renal inﬂammation. However, little is known on the
role of NLRP3 in hypertension. We have investigated the effect of NLRP3
inﬂammasome on blood pressure, plasma renin activity and concentration (PRA
and PRC), renal and cardiac hypertrophy in NALP3 and ASC deﬁcient mice on
which the two-kidney, one clip (2K1C) and the deoxycorticosterone-acetate
(DOCA)/salt models were applied. MBP, PRA, PRC, and HW/BW were
signiﬁcantly increased at week 12 in WT-2K1C mice compared to the sham.Neither NLAP3-KO nor ASC-KO 2K1C treated mice developed hypertension and
had lower circulating levels of PRA and PRC and serum amyloid A (SAA) and IL6
compared to the control. RNA levels of SAA, NLRP3, IL1b and IL1a were
increased in the ischemic kidney in C57BL/6J mice. Administration of anti-IL1b
antibody to the WT mice attenuated the increases of blood pressure and renin
in 2K1C mice. With chronic administration of DOCA/salt, MBPs in both NLRP3-
KO andWT mice were comparable and not signiﬁcantly increased compared to
tap water group. PRA and PRC in both NALP3-KO and WT mice were
signiﬁcantly suppressed by DOCA/salt. HW/BW and KW/BW in both DOCA/salt
treated NALP3-KO and WT mice were signiﬁcantly increased. DOCA/salt
induced hypokalemia was comparable between Nlrp3 KO and WT groups.
However, the heart and kidney index in DOCA/salt NLRP3-KO mice was
signiﬁcantly lower than that in DOCA/salt WT mice. Our data show that NLRP3
mediated IL1b is linked to development of renovascular hypertension and
suggest that a novel target for the treatment of hypertension. The results also
implicate that NLRP3 contributes to the development of cardiac and renal
hypertrophy independently of blood pressure in the DOCA/salt model.
http://dx.doi.org/10.1016/j.krcp.2012.04.586263
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Chronic kidney disease (CKD) and obesity are important public health
concerns. We examined the inﬂuence of dietary management and physical
exercises on renal function, lipid proﬁles and exercise tolerance of a group of
CKD patients. We enrolled 45 obese patients with CKD from stage 1 to 3b with
tailored by regular dietitian consultation, recommendations of adequate daily
protein and caloric intake, and physical exercises for body weight (BW)
reduction. The target was BW reduction Z 3%. Thirty eight obese CKD patients
completed the study and 24 patients reached the target. Patients who reached
the target was signiﬁcant larger in total body fat decrement than those who
failed (3.0% vs 0.5%, p ¼ 0.003). In addition, total muscle mass, especially on
trunk and lower limbs (1.2% vs 0%, P ¼ 0.026) was signiﬁcant decreased in
patients who reached the target compared to those who failed. The laboratory
data disclosed the signiﬁcant reduction of Chol (0.7% vs. -19.3%; P ¼ 0.007),
LDL-C ( 3.7% vs. -37.6%; P o 0.001), and UA (0% vs. -0.8%; P ¼ 0.025) between
the two groups. The cardiorespiratory endurance to complete 800 meters run
(375.1 7 64.7 sec vs. 327.1 7 84.0 sec; P ¼ 0.001), abdominal muscle strength
and endurance by times of sit-ups (13.6 7 9.1 number/min vs. 19.9 7 9.2; P ¼
0.005), and ﬂexibility of the lower back by sit and reach (18.8 7 10.8 cm vs.
27.8 7 10.9 cm; Po 0.001) of the patients who reached the target were
improved signiﬁcantly after 2-months of physical exercise training and
education.We conclude that combination of dietary management and exercises
are effective in improving health-related physical ﬁtness, blood pressure
control, dyslipidemia and renal function in overweight or obese CKD patients.
Supportive individualized programs for lifestyle change could exert beneﬁcial
effects. A longitudinal study with larger sample size is warranted to elucidate
the efﬁcacy of combination of dietary management and exercises.
http://dx.doi.org/10.1016/j.krcp.2012.04.587264
CXCL16 REGULATES ANGIOTENSIN II-INDUCED INFLAMMATION
AND PROTEINURIA
Yanlin Wang, Yunfeng Xia
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Hypertension is a major cause of chronic kidney disease. Recent studies have
shown that inﬂammation plays a critical role in the pathogenesis and
progression of hypertensive kidney disease. However, the signaling
mechanisms underlying the induction of inﬂammation are poorly understood.
We have found that CXCL16, a recently discovered chemokine, is induced in the
kidney in a murine model of angiotensin II (Ang II)-induced hypertension.
Therefore, we examined whether CXCL16 regulates inﬂammatory cell
inﬁltration and renal injury using CXCL16 knockout (CXCL16-KO) mice. Wild-
type (WT) and CXCL16-KO mice were treated with Ang II via subcutaneous
osmotic minipumps at 1500 ng/kg/min for up to 4 weeks. To accelerate renal
injury, all mice were subjected to unilateral nephrectomy and received 1% NaCl
in drinking water. WT and CXCL16-KO mice had virtually identical blood
pressure at baseline. Ang II treatment led to an increase in blood pressure that is
